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Abstract
Background: Serum antibodies against myelin-oligodendrocyte-glycoprotein (MOG-IgG) are detectable in a
proportion of patients with acute or relapsing neuroinflammation. It is unclear, if neuro-axonal damage occurs only in
an attack-dependent manner or also progressively. Therefore, this study aimed to investigate longitudinally intra-retinal
layer changes in eyes without new optic neuritis (ON) in MOG-IgG-seropositive patients.
Methods: We included 38 eyes of 24 patients without ON during follow-up (F/U) [median years (IQR)] 1.9 (1.0–2.2) and
56 eyes of 28 age- and sex-matched healthy controls (HC). The patient group’s eyes included 18 eyes without (EyeON-)
and 20 eyes with history of ON (EyeON+). Using spectral domain optical coherence tomography (OCT), we acquired
peripapillary retinal nerve fiber layer thickness (pRNFL) and volumes of combined ganglion cell and inner plexiform layer
(GCIP), inner nuclear layer (INL), and macular volume (MV). High-contrast visual acuity (VA) was assessed at baseline.
Results: At baseline in EyeON-, pRNFL (94.3 ± 15.9 μm, p = 0.36), INL (0.26 ± 0.03mm3, p = 0.11), and MV (2.34 ± 0.11
mm3, p = 0.29) were not reduced compared to HC; GCIP showed thinning (0.57 ± 0.07mm3; p = 0.008), and VA was
reduced (logMAR 0.05 ± 0.15 vs. − 0.09 ± 0.14, p = 0.008) in comparison to HC. Longitudinally, we observed pRNFL
thinning in models including all patient eyes (annual reduction − 2.20 ± 4.29 μm vs. − 0.35 ± 1.17 μm, p = 0.009) in
comparison to HC. Twelve EyeON- with other than ipsilateral ON attacks ≤ 6months before baseline showed thicker
pRNFL at baseline and more severe pRNFL thinning in comparison to 6 EyeON- without other clinical relapses.
Conclusions: We observed pRNFL thinning in patients with MOG-IgG during F/U, which was not accompanied by
progressive GCIP reduction. This effect could be caused by a small number of EyeON- with other than ipsilateral ON
attacks within 6 months before baseline. One possible interpretation could be a reduction of the swelling, which could
mean that MOG-IgG patients show immune-related swelling in the CNS also outside of an attack’s target area.
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Background
Antibodies against conformation-dependent epitopes of
myelin-oligodendrocyte-glycoprotein (MOG-IgG) have
been described in patients with central nervous system
(CNS) inflammation of putative autoimmune etiology [1–
4]. MOG is also the dominant antigen for demyelinating
antibodies in experimental autoimmune encephalomyelitis
(EAE), the predominant animal model of multiple scler-
osis (MS), and MOG-IgG can augment demyelination by
cell-mediated and humoral immune responses [1]. In
neuropathology studies, MOG-IgG are associated with
MS-like pathology directed against myelin and oligoden-
drocytes and biopsies present a MS pattern II [5, 6].
MOG-IgG affinity-purified from the blood of patients with
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optic neuritis (ON) enhanced inflammation and induced
demyelination upon transfer into experimental animals in-
dicating the pathogenic potential of MOG-IgG detected in
the blood of these patients [7]. It is discussed whether
MOG-IgG define a separate disease entity tentatively
called MOG-IgG-associated diseases, MOG-IgG auto-
immunity or MOG-IgG seropositive encephalomyelitis ra-
ther than being part of several autoimmune disorders,
especially neuromyelitis optica spectrum disorders
(NMOSD) [1, 3, 8, 9]. However, the bouquet of clinical
phenotypes in MOG-IgG-associated diseases at clinical
onset is not easy to differentiate and overlaps with
aquaporin-4-IgG (AQP4-IgG)-seropositive NMOSD and
in rare cases with MS [2, 10–12], although distinct clinical
features such as seizures have been described [13–15].
ON is the most common manifestation and can lead to
substantial neuro-axonal damage after multiple relapses,
as shown in different cohorts [11, 16]. The pattern of ret-
inal degeneration after ON seems to be similar in all
MOG-IgG-seropositive cohorts as shown by optical co-
herence tomography (OCT) studies [11, 16]. OCT proved
to be a precise and reproducible method for non-invasive
visualization and quantification of retinal layers and plays
a crucial role in analyzing retinal changes in various neu-
roinflammatory disorders [17–20]. In a cross-sectional
study, MOG-IgG-related OCT features indicated subclin-
ical pathology in eyes without a history of ON (EyeON-)
[16]. However, no longitudinal OCT data is reported in
MOG-IgG-associated diseases so far and the pattern of
longitudinal retinal damage still remains elusive. Using
OCT, we assessed retinal layer thinning as a marker of
neuro-axonal damage in a cohort of MOG-IgG-
seropositive patients without ON during follow-up (F/U).
We aimed to investigate at baseline and longitudinally
microstructural changes in MOG-IgG-seropositive pa-
tients, extending previous work in AQP4-IgG-seropositive
NMOSD [21, 22].
Methods
Study populations
Twenty-four patients were seen and followed [F/U (years;
median (inter-quartile-range (IQR))) 1.9 (1.0–2.2)] at four
university tertiary care centers specialized in neu-
roimmunological diseases (Institute of Clinical Neuroim-
munology, Ludwig Maximilians University (LMU),
Munich, Germany, N = 11; NeuroCure Clinical Research
Center, Charité – Universitätsmedizin Berlin, Germany,
N = 10; Department of Neurology, University of Lille Hos-
pital, Lille, France, N = 1; Department of Neurology, Klini-
kum Rechts der Isar, Technische Universität München
(TUM), Munich, Germany, N = 2). Written informed con-
sent was obtained from all patients participating in the
study. The local ethics committees approved the study
protocol in accordance with the Declaration of Helsinki
(1964) in its currently applicable version. All patients were
matched by age (W = 370, p = 0.542) and sex (χ2 = 0,937,
p = 0.333) to 56 eyes of 28 healthy controls (HC; F/U)
[years; median (IQR)] 1.9 (1.9–2.3) from the NeuroCure
Clinical Research Center, Charité – Universitätsmedizin
Berlin, Germany. Inclusion criteria were the detection of
MOG-IgG, complete longitudinal clinical and OCT im-
aging data with minimum F/U of 8months and age be-
tween 15 and 75 years at baseline. Only eyes without
concomitant potentially confounding diseases (glaucoma,
diabetes mellitus, retinal surgery, retinal disease, ametro-
pia > 6 diopters) were included. Eyes with a history of ON
≤ 5months before baseline were excluded. Clinical data
(diagnosis, disease onset, number of ON, date last ON,
brain attacks, myelitis, EDSS, relapses, treatment history)
were collected for all patients. For detection of MOG-IgG,
serum samples from all patients were analyzed at least
once by established cell-based assays at the discretion of
each center using the laboratory’s cutoffs (MOG IFT,
EUROIMMUN, Laboratory Stöcker, Germany; Molecular
Neuroimmunology Group, University Heidelberg, Heidel-
berg, Germany; Reindl Lab, Medical University of Inns-
bruck, Innsbruck, Austria; Meinl Lab, LMU, Munich,
Hemmer Lab, TUM, Munich) [3, 7, 23].
Optical coherence tomography
All centers used SPECTRALIS spectral-domain OCT
(Heidelberg Engineering, Heidelberg, Germany) with
automatic real-time (ART) function for image aver-
aging. We acquired peripapillary retinal nerve fiber
layer thickness (pRNFL) and volumes of combined
ganglion cell and inner plexiform layer (GCIP), inner
nuclear layer (INL) and macular volume (MV) by
OCT. GCIP, INL and MV were calculated as a 3 mm
diameter cylinder around the fovea from a macular
volume scan (25° × 30°, 61 vertical B-scans, 12 ≤
ART ≤ 18; 20° × 20°, 25 vertical B-scans, 27 ≤ART ≤
49). The peripapillary RNFL (pRNFL) was measured
with activated eye tracker using ring scans around the
optic nerve (12°, 1536 A-scans, 57 ≤ART ≤ 100) or
the most inner ring of a star-and-ring scan around
the optic nerve (12°, 768 A-scans, 27 ≤ART ≤ 33). For
two patients (8.3%), the ring scan protocol changed
during the acquisition period (ring scan to inner ring
of a star-and-ring scan). Segmentation of all layers
was performed semi-automatically using software pro-
vided by the OCT manufacturer (Eye Explorer
1.9.10.0 with viewing module 6.3.4.0, Heidelberg En-
gineering, Heidelberg, Germany). Experienced raters
(BK for TU Munich data, JH for all other data) care-
fully checked all scans for sufficient quality and seg-
mentation errors and corrected if necessary. OCT
data in this study is reported and analyzed according
to the APOSTEL and OSCAR-IB recommendations
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[24, 25]. Macular microcysts were defined as the pres-
ence of cystic lesions on at least one scan detected by
experienced raters (BK for TU Munich scans, JH for
all other scans). Additionally, we collected habitually
corrected monocular high-contrast visual acuity (VA)
using ETDRS (Early Treatment Diabetic Retinopathy
Study) charts at baseline in 20 ft distance for a subset
of patients (N = 15).
Statistical methods
Group differences between MOG-IgG patients and HC
were tested by chi-squared test for sex and Wilcoxon
rank-sum test for age. Main outcomes were change of
GCIP, pRNFL, INL and MV and VA over F/U. Cross-
sectional differences of OCT values and VA between all
groups were analyzed pairwise by generalized estimating
equation (GEE) models to account for inter-eye within-
patient correlations of monocular measurements. Longi-
tudinal analyses of OCT and VA were performed with
linear mixed effects models using time from baseline
and group as fixed effects and patient-ID and eye-ID as
random effects; results are reported for effect “Time
from Baseline * Group”, which reflects the group-
specific change over time. Annual loss was estimated for
each individual as change to baseline at last visit divided
by F/U time in years. All tests and graphical representa-
tions were performed with R version 3.3.1 [http://www.
R-project.org]. Statistical significance was established at
p < 0.05, and all results were interpreted in the context
of an exploratory analysis and therefore not adjusted for
multiple comparison.
Results
Cohort description and follow-up
We included 38 eyes of 24 patients without ON during
F/U. 70% of the patients from Berlin [7/10] and 64% of
the patients from LMU Munich [7/11] have been in-
cluded in previous cross-sectional studies [7, 10, 16].
MOG-IgG-seropositive patients had the following diag-
nosis: recurrent ON (N = 7), MOG-IgG-seropositive
NMOSD (N = 12) meeting the 2015 IPND (International
Panel for Neuromyelitis Optica Diagnosis) criteria for
seronegative NMOSD [26], MOG-IgG-seropositive MS
(N = 3) and MOG-IgG-seropositive meningoencephalo-
myelitis (N = 2). All patients had ≥ 1 F/U visit(s) [median
(range) 2 visits (2–7)]. The MOG-IgG-seropositive co-
hort included 18 eyes without (EyeON-) and 20 eyes with
a history of ON (EyeON+) (number of ONs [median
(range)] 0 (0 – 8); time since ON in years [median
(range)] 2.2 (0.4 – 14.9)). From the 18 EyeON-, we identi-
fied 12 eyes with other than ipsilateral ON attacks
within 6 months before baseline (five eyes of three pa-
tients with a myelitis, four eyes of two patients with
myelitis and brainstem attacks, one eye of one patient
with myelitis and contralateral ON and 2 eyes of 2 pa-
tients with contralateral ON; age 40 ± 9, male/female 5/
3, EDSS 2.5, median follow-up 14 ± 5.9 months)) and six
eyes without other attacks (age 39.0 ± 21.0, male/female
1/4, EDSS 3.5, median follow-up 26 ± 4.5 months).
Retrospectively, one patient (2 eyes) could not be in-
cluded in the study analysis because he had ONs on
both sides during F/U and another patient (2 eyes) could
not be included because he had insufficient follow-up
less than 8 months. Data of further 8 eyes had to be ex-
cluded (five eyes with ON during F/U, one eye with ON
less than 5months before study inclusion, one eye with
missing data, one eye with OCT-confounding disease).
Clinical characteristics of all included patients are shown
in Table 1.
Group differences at baseline
First, we analyzed group differences at baseline between
MOG-IgG-seropositive patient eyes with a history of
ON (EyeON+), patient eyes without previous ON
(EyeON-) and eyes from HC. At baseline, in EyeON-,
pRNFL, INL and MV were not significantly different,
but GCIP was significantly thinner in comparison to HC
(p = 0.008) (Table 2, Fig. 1). VA was lower in EyeON- in
comparison to HC (p = 0.013).
In EyeON+ at baseline pRNFL, GCIP and MV were sig-
nificantly lower in comparison to HC (pRNFL p <
0.0001, GCIP p < 0.0001, MV p < 0.0001). In contrast,
INL was significantly thicker in EyeON+ (INL 0.30 ± 0.05
mm3 vs. 0.27 ± 0.03 mm3 (p = 0.046)). VA was also lower
in EyeON+ (0.55 ± 0.81) in comparison to HC [− 0.09
(0.14), p = 0.01) and EyeON- [0.05 (0.15), p = 0.058).
One EyeON- showed a massive thinness of the pRNFL at
baseline despite a missing history of ON. We found macu-
lar microcysts within the INL in 6/20 (30%) EyeON+.
OCT changes during F/U
Longitudinally, we observed pRNFL thinning, which was
not accompanied by progressive GCIP reduction, in eyes
without ON during F/U (annual loss: − 2.20 ± 4.29 μm
vs. HC -0.35 ± 1.17 μm, p = 0.009) (Fig. 2; individual
changes in Additional file 1). There were no longitudinal
group differences between EyeON+ and EyeON- for GCIP,
pRNFL, INL and MV as well as between MOG-IgG-
seropositive NMOSD and other MOG-IgG-seropositive
patients (Table 3). In a previous study investigating
spinal cord changes in MOG-IgG patients, we suspected
edematous changes in patients close to a clinical attack
[27]. We therefore investigated patients with a non-
ipsilateral ON attack within 6 months of the baseline
visit in a subgroup analysis. At baseline, the pRNFL in
12 EyeON- with a non-ipsilateral ON attack within the 6
months before baseline was thicker in comparison to 6
EyeON- without a non-ipsilateral ON attack within the 6
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months before baseline (pRNFL 100.2 ± 12.7 μm vs.
82.7 ± 16.2 μm (p = 0.019)) (Fig. 3A). Reduction of
pRNFL thickness was seen mainly in 3 eyes of the sub-
group analysis. Two of the 3 eyes had no clinical evi-
dence of unilateral ON attacks of the contralateral eye
within the 6 months prior to inclusion in the study. One
of the 3 eyes had a relapse complex with myelitis, brain
attack and contralateral ON within 6 months prior to
baseline. An ON-affection of these 12 EyeON- with a
non-ipsilateral ON attack was further ruled out by a
stable high-contrast visual acuity (HCVA) without a
change during F/U (HCVA as decimal, median (range):
at baseline 1.0 (0.6–1.1); at last visit 1.0 (0.6–1.6)). A
longitudinal graphical display of EyeON- showed the
pRNFL thinning to be predominantly present in EyeON-
with an attack before baseline (Fig. 3B). However, due to
the small sample size, no statistical analysis could be
performed.
Discussion
In this study, we investigated longitudinally, MOG-
IgG-seropositive patients for potential progressive or
covert damage in the retina in the absence of new
clinical ON. We could not detect progressive GCIP
thinning during F/U in MOG-IgG-seropositive pa-
tients, which is in contrast to progressive GCIP
Table 1 Clinical characteristics of patients. Age (W = 370, p = 0.542) and sex (χ2 = 0.937, p = 0.333) did not differ between MOG-IgG-
seropositive patients and HCs
HC MOG-IgG-seropositive patients
Subjects [N] 28 24
Number of eyes [N] 56 38
F/U [median years (min, max)] 1.9 (0.8–3.3) 1.9 (0.6–2.8)
Age [mean (SD)]; [range at baseline] 43.12 (9.76); [11–68] 40.66 (13.53); [15–68]
Sex [male (%)] 6 (21.4) 9 (37.5)
Clinical phenotypes (MOG-IgG-associated diseases) – ON (N = 7), NMOSD (N = 12), MS (N = 3), meningoencephalomyelitis (N = 2)
EDSS at baseline [median (IQR)] – 2.5 (2.0; 3.0)
Disease duration at baseline in years [median (IQR)] – 3.0(1.1; 8.8)
Eyes with a history of ON [EyeON+, N (%)] – 20 (52.6%)
Patients with a history of ON [N (%)] – 15 (62.5%)
Number of ON in EyeON+ [median (range)] – 2 (1–8)
Eyes without a history of ON [EyeON-, N (%)] – 18 (47.4%)
Time since ON [years; median (range)] – 2.2 (0.4–14.9)
Eyes with contralateral ON during F/U [N (%)] – 5 (13.2)
Treatment at baseline [N] – AZA [4], MTX [1], NAT [1], RIX [8], IVIG [1], PRED [2], NONE [7]
Abbreviations: HC healthy controls, N number, SD standard deviation, F/U follow-up, AZA azathioprine, MTX methotrexate, NAT natalizumab, RIX rituximab, IVIG
intravenous immunoglobulins, PRED prednisone, TOC tocilizumab, MMF mycophenolate mofetil, NONE no treatment
Table 2 Baseline OCT results of MOG-IgG-seropositive patients and HCs
Baseline results HC MOG-IgG-
seropositive
patients EyeON-
MOG-IgG-
seropositive
patients
EyeON+
HC vs EyeON- HC vs EyeON+ EyeON- vs EyeON+
N (eyes) = 56 N (eyes) = 18 N (eyes) = 20 [B] [SE] [p] [B] [SE] [p] [B] [SE] [p]
GCIP [mean (SD)] 0.63 (0.04) 0.57 (0.07) 0.39 (0.12) − 0.057 0.022 0.008 − 0.235 0.033 < 0.0001 − 0.178 0.037 < 0.0001
pRNFL [mean (SD)] 98.50 (9.17) 94.33 (15.92) 58.25 (22.56) − 4.167 4.577 0.360 − 40.25 5.864 < 0.0001 − 36.08 6.311 < 0.0001
INL [mean (SD)] 0.27 (0.03) 0.26 (0.03) 0.30 (0.05) − 0.014 0.009 0.110 0.026 0.013 0.046 0.041 0.014 0.004
MV [mean (SD)] 2.37 (0.10) 2.34 (0.11) 2.19 (0.13) − 0.036 0.034 0.290 − 0.183 0.039 < 0.0001 − 0.147 0.042 0.0005
HCVA in logMAR
[mean (SD)]
−0.09 (0.14) 0.05 (0.15) 0.55 (0.81) 0.146 0.059 0.013 0.394 0.134 0.0032 0.248 0.131 0.058
Abbreviations: B estimate, GCIP combined ganglion cell and inner plexiform layer, HC healthy control, INL inner nuclear layer, EyeON- MOG-IgG-seropositive patients
without a history of ON, EyeON+ MOG-IgG-seropositive patients with a history of ON, OCT optical coherence tomography, ON optic neuritis, p p value, pRNFL
peripapillary retinal nerve fiber layer, SD standard deviation, SE standard error, MV macular volume, vs versus, N number of eyes
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reduction in AQP4-IgG-seropositive NMOSD and MS
[22, 27]. Instead, we observed a longitudinal pRNFL
reduction, which in a consequent subgroup analysis
appeared to primarily occur in patients with non-
ipsilateral ON attacks within 6 months before base-
line. A hypothetical explanation of this finding could
be a remission of pRNFL edema.
Cross-sectional retinal imaging studies have shown
conflicting results as to whether MOG-IgG-
associated diseases have a more favorable outcome
compared to patients with ON in other disease con-
texts [28–34]. The presumed higher relapse rates in
MOG-IgG-seropositive patients could be associated
with a severe retinal neuroaxonal loss and an un-
favorable visual outcome [11]. Although OCT data
regarding MOG-IgG-associated retinal damage are
inconsistent [11, 16, 30, 35], neuroaxonal retinal
damage may occur as a consequence of clinical epi-
sode(s) of ON or of subclinical involvement [11, 16].
ON was associated with macular microcysts, a bio-
marker suggestive of severe optic neuropathy [16, 36,
37]. A previous study investigating a smaller cohort
of MOG-IgG-positive patients showed a significant
reduction of the pRNFL and the ganglion cell layer
in EyeON- compared to HC cross-sectionally [16]. By
contrast, in our current study, we could only con-
firm a significant GCIP reduction in EyeON- at base-
line but no significant reduction of the pRNFL as a
hint towards subclinical retinal pathology. However,
pRNFL edema as a marker of immune-related swell-
ing in the CNS after relapses and also outside of re-
lapses could have contributed to this finding. The
GCIP reduction at baseline could be discussed as
progressive neurodegenerative retinal involvement,
subclinical optic nerve pathology, chiasmal crossover
of ON in contralateral eyes, or as an expression of
subclinical ON in the previous patient’s history.
However, according to Ramanathan et al., only 5% of
ONs in MOG-IgG-seropositive patients shows chias-
mal involvement [38].
Longitudinally, we observed pRNFL but not GCIP thin-
ning. We hypothesize that this can be explained not only
Fig. 1 Baseline data: bee swarm plots of cross-sectional OCT data for HC (gray, left), MOG-IgG-seropositive EyeON- (blue, middle) and MOG-IgG-
seropositive Eye ON+ (red, right) (median ± IQR, single eyes as dots) for a pRNFL, b GCIP, c INL, and d MV. Abbreviations: Eye ON-: MOG-IgG-
seropositive eyes without a history of ON; Eye ON+: MOG-IgG-seropositive eyes with a history of ON; GCIP: combined ganglion cell and inner
plexiform layer; HC: Healthy control; INL: inner nuclear layer; IQR: inter-quartile range; OCT: Optical coherence tomography; p: p value; pRNFL:
peripapillary retinal nerve fiber layer; MV: macular volume
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by subclinical retinal or optic nerve involvement or drug-
induced retinal damage related to immunosuppressive
treatment, but also by a remission of non-ipsilateral ON at-
tacks that has occurred in EyeON- within 6 months before
baseline since patients without clinical attacks ≤ 6 months
before baseline did not present significant pRNFL or GCIP
loss during F/U. This is clearly in contrast to our recently
published data about longitudinal GCIP thinning in
AQP4-IgG-seropositive NMOSD [22] or earlier studies
reporting GCIP loss in MS [27] and might be an import-
ant hint towards the differentiation of MOG-IgG-
associated diseases from AQP4-IgG-seropositive NMOSD.
AQP4-IgG-seropositive NMOSD is an astrocytopathy,
and a primary retinopathy caused by antibody-mediated
damage is supported by animal studies and recently also
clinical studies [22, 39]. In contrast, the retina does not
harbor myelin-producing oligodendrocytes and an
expression of MOG has not been shown, making a
primary retinopathy unlikely.
Further, data showing clear differences between AQP4-
IgG-seropositive NMOSD and MOG-IgG-associated dis-
eases were presented recently by Chien et al. [40]. Spinal
cord imaging data showed differences in spinal cord affec-
tion patterns and disability accumulation. A higher preva-
lence of myelitis with clinical attacks and chronic spinal
cord lesions was detected for AQP4-IgG-seropositive
NMOSD patients in comparison to MOG-IgG-associated
diseases [40]. Interestingly, MOG-IgG-seropositive
Fig. 2 Bar graphs of longitudinal OCT data. Plotted change (mean ± standard error) for rounded time since baseline in years for a pRNFL and b
GCIP, c MV for eyes of MOG-IgG-seropositive patients (blue, dashed), and HC (gray, continuous), displayed until median F/U time (2 years).
Abbreviations: F/U: follow-up; GCIP: combined ganglion cell and inner plexiform layer; HC: healthy control; INL: inner nuclear layer; Eye ON-: MOG-
IgG-seropositive eyes without a history of ON; ON: optic neuritis; OCT: optical coherence tomography; pRNFL: peripapillary retinal nerve fiber layer;
SE: standard error, MV: macular volume. F/U investigations were rounded up or down to the year 0, 1, or 2 and follow-up visits with a time since
baseline < 6months were excluded from the graphical display. N rounded for timepoints: T0: N (MOG) = 38 eyes, T1: N (MOG) = 27 eyes, T2: N
(MOG) = 26 eyes, T0: N (HC) = 56 eyes, T1: N (HC) = 41 eyes, T2: N (HC) = 40 eyes
Table 3 Longitudinal OCT results of MOG-IgG-seropositive patients and HCs
Longitudinal OCT
data
HC MOG-IgG-
seropositive
patients EyeON-
MOG-IgG-
seropositive
patients EyeON+
HC vs MOG-IgG-seropositive
patients (EyeON- and EyeON+)
EyeON- vs EyeON+
Absolute change to baseline
N (eyes) = 56 N (eyes) = 18 N (eyes) = 20 [B] [95%CI] [SE] [p] [B] [95%CI] [SE] [p]
GCIP [mean (SD)] 0.00 (0.01) 0.00 (0.01) 0.00 (0.05) − 0.000 − 0.004; 0.005 0.002 0.884 − 0.006 − 0.016; 0.003 0.005 0.214
pRNFL [mean (SD)] − 0.61 (2.00) − 4.5 (5.89) − 1.60 (4.48) − 1.645 − 2.819;
− 0.471
0.599 0.009 0.168 − 1.380; 1.717 0.790 0.832
INL [mean (SD)] 0.00 (0.01) 0.01 (0.02) 0.00 (0.03) 0.002 −0.002; 0.005 0.002 0.312 − 0.003 − 0.011;
0.004
0.004 0.381
MV [mean (SD)] 0.00 (0.02) − 0.01 (0.04) − 0.01 (0.05) − 0.008 − 0.016; 0.0013 0.004 0.103 0.002 − 0.013; 0.018 0.008 0.769
Abbreviations: 95%CI 95% confidence interval, B Estimate (beta-coefficient), GCIP combined ganglion cell and inner plexiform layer, HC healthy control, INL inner
nuclear layer, EyeON- MOG-IgG-seropositive patients without a history of ON, EyeON+ MOG-IgG-seropositive patients with a history of ON, OCT optical coherence
tomography, p p value, pRNFL peripapillary retinal nerve fiber layer, SD standard deviation, SE standard error, MV macular volume, vs versus, N number of eyes
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patients showed a swelling of the upper cervical cord area
during other non-myelitis attacks, also pointing towards a
systemic inflammatory affection in MOG-IgG-associated
diseases as potentially shown here in the pRNFL during
different attacks [40]. Our data is in line with the conclu-
sion that AQP4-IgG-seropositive NMOSD and MOG-
IgG-associated diseases are distinct immunological disor-
ders, but share common clinical patterns [22, 40–42].
Limitations of our study are the heterogeneity of
MOG-IgG-seropositive patients with different clinical
phenotypes in our cohort, the heterogeneity of immuno-
suppressive treatments of our patients, and due to the
rarity of MOG-IgG-seropositive patients in Europe, the
small sample size, which leads to outliers possibly having
a larger effect on the results, short and variable F/U, and
the evaluation of MOG-IgG by different labs using dif-
ferent assays. Additionally, our study lacks magnetic res-
onance imaging data on optic nerve lesion lengths and
lesion volumes of the afferent visual system as well as
whole-brain lesion volume to further evaluate subclinical
retinal atrophy in MOG-IgG-associated diseases.
Conclusions
We report in this small explorative study of MOG-IgG-
associated diseases no evidence of GCIP thinning during
F/U. Additionally, we found pRNFL reduction without
GCIP loss during F/U predominantly in EyeON- with
other than ipsilateral ON attacks ≤ 6 months before
baseline. We will investigate in a planned longitudinal
study involving more centers, whether this reduction is
actually due to a remission of edema or reflects retinal
neurodegenerative processes or drug-induced retinal
damage related to aggressive immunosuppressive
treatment.
Additional file
Additional file 1: Figure S1. Spaghetti plots of longitudinal OCT data.
Plotted absolute values of all subjects for time since baseline in years for
(A) pRNFL and (B) GCIP, (C) MV for eyes of MOG-IgG-seropositive patients
(turquoise) and HC (red), as well as (D) plotted absolute values of all Eye-
sON- with (green) and without (red) an attack in the 6 months before
baseline. Abbreviations: GCIP: Combined ganglion cell and inner plexi-
form layer, HC: Healthy control, Eye ON-: MOG-IgG-seropositive eyes with-
out a history of ON, ON: Optic neuritis, OCT: Optical coherence
tomography, pRNFL: Peripapillary retinal nerve fiber layer, MV: Macular
volume. (TIFF 47160 kb)
Abbreviations
AQP4-IgG: Aquaporin-4 antibodies; ART: Automatic real time; B: Estimate;
CNS: Central nervous system; EAE: Experimental autoimmune
encephalomyelitis; EDSS: Expanded disability status scale; EyeON-: Eyes
without a history of optic neuritis; EyeON+: Eyes with a history of optic
neuritis; F/U: Follow-up; GCIP: Combined ganglion cell and inner plexiform
layer; GEE: Generalized estimated eq.; HC: Healthy control; INL: Inner nuclear
layer; IQR: Inter-quartile range; LMU: Ludwig-Maximilians University Munich;
MOG-IgG: Myelin-oligodendrocyte glycoprotein antibodies; MS: Multiple
sclerosis; N: Number; NCRC: NeuroCure Clinical Research Center Berlin;
NMOSD: Neuromyelitis optica spectrum disorders; OCT: Optical coherence
tomography; ON: Optic neuritis; p: p value; pRNFL: Peripapillary retinal nerve
Fig. 3 a Bee swarm plots of cross-sectional OCT data for HC (gray, left), EyeON- with non-ipsilateral ON attacks ≤ 6 months before baseline (blue,
middle), and EyeON- with no attacks ≤ 6 months before baseline (blue, right) (median ± IQR, single eyes as dots) for pRNFL. b Bar graphs of
longitudinal OCT data. Plotted change (mean ± standard error) for rounded time since baseline for pRNFL of EyeON- with other attacks (blue,
dashed) and EyeON- without other attacks (blue, continuous), displayed until median F/U time. F/U investigations were rounded up or down to
the year 0, 1, or 2 and follow-up visits with a time since baseline < 6months were excluded from the graphical display. EyeON-attack- T0/1/2: N = 6
eyes, EyeON-attack- T0: N = 12 eyes, T1: N = 11 eyes, T2: N = 3 eyes. Abbreviations: F/U: follow-up; HC: healthy control; Eye ON-: MOG-IgG-seropositive
eyes without a history of ON; ON: optic neuritis; OCT: optical coherence tomography; pRNFL: peripapillary retinal nerve fiber layer; N: number of
eyes that contributed to the analysis
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fiber layer; SD: Standard deviation; SE: Standard error; MV: Macular volume;
TUM: Technical University Munich; VA: Visual acuity
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